Note the timeline
$Ocugen(OCGN.US$ Ocugen Announces Dosing Completion of Subjects With Stargardt Disease in Cohort 2 of Phase 1/2 Gardian Clinical Trial of Ocu410St—a Modifier Gene Therapy! Expected to announce results in Q3 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
